Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 73 publications
Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies.
Journal: Infectious diseases and therapy
Published: February 25, 2026
Integrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent Clostridioides difficile infection from five prospective clinical trials: an update.
Journal: Therapeutic advances in gastroenterology
Published: June 12, 2025
Neisseria sicca Vertebral Osteomyelitis: A Case Report and Literature Review.
Journal: Journal of clinical medicine
Published: October 24, 2024
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS.
Journal: Inflammatory bowel diseases
Published: August 09, 2024
Deep Sternal Wound Infection Caused by Rhizopus Species After Coronary Artery Bypass Graft.
Journal: Open forum infectious diseases
Published: February 27, 2024
Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled Trial.
Journal: Gastroenterology
Published: January 29, 2024
Managing Recurrent Vulvovaginal Candidiasis.
Journal: Journal of women's health (2002)
Published: October 04, 2023
COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients.
Journal: Scientific reports
Published: September 22, 2023
Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections.
Journal: Open forum infectious diseases
Published: September 11, 2023
A Case of Sustained Viral Shedding of Mpox With Ocular Involvement Resulting in Vision Loss.
Journal: Open forum infectious diseases
Published: July 14, 2023
Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?
Journal: Infection and drug resistance
Published: March 23, 2023
Safety of fecal microbiota, live-jslm (REBYOTA™) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials.
Journal: Therapeutic advances in gastroenterology
Published: December 21, 2022
Last Updated: 09/26/2026